Canterbury DHB

Context

Palliative Care

Early referral to the Palliative Care Service is very important.

In This Section

Low dose cytarabine as per AML14 trial

Etoposide/Thioguanine

Hydroxyurea

Hyperleucocytosis

Low dose cytarabine as per AML14 trial

Etoposide/Thioguanine

Schedule

Etoposide (VP16)

50 mg Daily PO

Thioguanine

40 mg Daily PO

Hydroxyurea

Hydroxyurea on a daily basis (up to 3–4 g orally per day) can also be valuable, especially:

Hyperleucocytosis

Recent reviews have not shown a benefit of leukapheresis for patients with very high white counts.

Reference

Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier M-C, Beyene J, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis. Leukemia Research. 2014 April;38(4):460-68.

About this Canterbury DHB document (4295):

Document Owner:

Ruth Spearing (see Who's Who)

Issue Date:

October 2018

Next Review:

October 2020

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4295